Fact 1 40 of women have dense breasts RESULT Current 2D mammography makes it difficult to detect cancers in dense breast tissue because both appear white in the image Source http ID: 659981
Download Presentation The PPT/PDF document "3D Mammography A Breakthrough in Cancer ..." is the property of its rightful owner. Permission is granted to download and print the materials on this web site for personal, non-commercial use only, and to display it on your personal computer provided you do not modify the materials and that you retain all copyright notices contained in the materials. By downloading content from our website, you accept the terms of this agreement.
Slide1
3D Mammography
A Breakthrough in Cancer DetectionSlide2
Fact 1:
40
% of women have dense
breasts.
RESULT:
Current 2D mammography makes it difficult
to detect
cancers in dense breast tissue because both appear white in the image.
Source: http
://www.cnn.com/2015/04/21/health/dense-breast-diagnosis/Slide3
Fact 2:
10%-20% of women (nationally) get called back for additional imaging as a result of unclear results from 2D screening.
RESULT:
More
expensive;
additional
anxiety
for the
patient
.
Source
: http://www.advisory.com/research/imaging-performance-partnership/the-reading-room/2013/09/benchmarking-screening-and-diagnostic-mammographySlide4
Fact 3:
Other imaging modalities like ultrasound and MRI are often used to help find cancers that can’t be seen on standard mammograms, but both modalities have higher rates of false-positive findings.
This often results in more tests and unnecessary biopsies, making MRI and ultrasound more expensive to implement in high-volume screening programs.
Source
: http://viewer.zmags.com/publication/7fee9aa9#/7fee9aa9/18Slide5
What is Breast
Tomosynthesis
?
Tomo
, or 3D mammography, is a
breakthrough
breast cancer detection.Slide6
How Does It Work?
Tomo
takes a series of 40-80 images,
versus 2-4 images
from traditional 2D
mammography.
RESULT
:
much greater
visibiliy
of breast tissue structures and possible cancers.Slide7
Benefits:
30-41% improved breast cancer detection, especially of invasive cancers
Up to 80% decrease in call backs for additional imaging
RESULT:
Reduction in healthcare costs due to earlier detection, as well as avoided follow-up testing.Slide8
Findings:
“Our findings are extremely promising, showing an overall relative increase in the cancer detection rate of about 30
%.”
~ Per
Skaane
, Oslo University Hospital, Norway
Tomosynthesis
not only improved the cancer detection rate in women with dense breasts, it also helped increase detection for women in the ‘fatty breast’ BI-RADS categories.
Source: http://viewer.zmags.com/publication/7fee9aa9#/7fee9aa9/18Slide9
American College of Radiology says…
“To
facilitate
large
scale outcome data collection, the technology must be widely available. Availability is greatly impacted by reimbursement for the service provided. The College applauds the decision by the Centers for Medicare and Medicaid Services (CMS) to facilitate access to these exams by covering beneficiaries for
tomosynthesis
and urges private payers to do the same.
”
“To
be clear:
tomosynthesis
is no longer investigational.
Tomosynthesis
has been shown to improve key screening parameters compared to digital mammography.
”
ACR Statement on Breast
Tomosynthesis
November 24,
2014
www.acr.orgSlide10
JAMA
“The addition of
tomosynthesis
to digital mammography yields significantly better performance outcomes when compared with screenings using digital mammography alone. “
I
nvasive
cancer detection
increased by 41%.
Patient recall rate decreased by 15%.
http://jama.jamanetwork.com/issue.aspx?journalid=67&issueid=930408Slide11
Not All Tomosynthesis
Equipment is Equal.
SDMI selected the GE
SenoClaire
technology because it delivers NO MORE radiation to the patient.Slide12
What’s the Difference?
GE
SenoClaire
No additional radiation than 2D
mammo
because it performs 3D and 2D imaging simultaneously.
SAFER for patients!
Hologic
2.4 times more radiation than 2D
mammo
because it conducts 2D and 3D imaging separately.Slide13
Low Dose SenoClaire
(1)
: Dosimetry for DBT systems
(2)
13
Reference value = EUREF limits
Source
: (1) Low Dose: The dose of a SenoClaire 3D view is equivalent to that of a 2D standard acquisition of the same view
."
(2) N.W
. Marshall and H.
Bosmans
, Medical Physics UZ Leuven,
Application of the draft EUREF protocol for Quality Control of digital breast
tomosynthesis
(
DBT) systems”, BHPA
2014.
GE SenoClaire
Hologic Genius
Siemens 3D Mammography
SenoClaire delivers the same amount of dose as a digital mammography acquisition in the same viewSlide14
Conclusion:
Tomosynthesis
is no longer considered an investigative technology. Evidence from numerous studies demonstrates the irrefutable conclusion that 3D mammography is not only better for patients with dense breasts, but ALL patients.
Increased cancer detection
Reduced number of call-backs and false-positives
No more radiation to patient
Fewer follow-up testing and biopsies
Win for Patients and WIN for Teacher’s Health Trust!Slide15
Watch Deb’s Video on Facebook
Thank you for choosing SDMI as your imaging partner!